Form 144 ROIVANT SCIENCES LTD. For: 8 April
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd stock price live, this page displays NASDAQ ROIV stock exchange data. View the ROIV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Roivant Sciences Ltd real time stock price chart below.
What Is the Roivant Sciences Ltd Stock Price Today?
The Roivant Sciences Ltd stock price today is 29.390.
What Is the Stock Symbol for Roivant Sciences Ltd?
The stock ticker symbol for Roivant Sciences Ltd is ROIV.
Is ROIV the Same as $ROIV?
$ROIV is a common way to refer to the Roivant Sciences Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Roivant Sciences Ltd Trade On?
Roivant Sciences Ltd is listed and trades on the NASDAQ stock exchange.
Is Roivant Sciences Ltd a Good Stock to Buy?
Determining whether Roivant Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Roivant Sciences Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ROIV quote. (ISIN: BMG762791017)
What Is the Roivant Sciences Ltd Stock Price Today?
The Roivant Sciences Ltd stock price today is 29.390.
What Is the Stock Symbol for Roivant Sciences Ltd?
The stock ticker symbol for Roivant Sciences Ltd is ROIV.
Is ROIV the Same as $ROIV?
$ROIV is a common way to refer to the Roivant Sciences Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Roivant Sciences Ltd Trade On?
Roivant Sciences Ltd is listed and trades on the NASDAQ stock exchange.
Is Roivant Sciences Ltd a Good Stock to Buy?
Determining whether Roivant Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Roivant Sciences Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ROIV quote. (ISIN: BMG762791017)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.855
29.490
52 wk Range
9.895
30.330
ROIV is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.85529.490
52 wk Range
9.89530.330
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ROIV Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
33.750
Upside
+14.83%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
- Form 8K Roivant Sciences Ltd. For: 2 April
- Investing.com
- Form 144 ROIVANT SCIENCES LTD. For: 8 April
- Investing.com
- Form 8K Roivant Sciences Ltd. For: 2 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd Earnings Call Summary for Q3/2026
- Roivant Sciences missed Q3 2026 estimates with EPS of -$0.38 (vs -$0.31 forecast) and revenue of $1.99M (vs $5.13M forecast), yet stock surged 14.52% pre-market to $24.21
- Company maintains strong cash position of $4.5B despite financial challenges, with non-GAAP net loss of $167M and elevated R&D ($165M) and G&A ($175M) expenses
- CEO Matt Gline emphasized focus on 'first-in-class orphan inflammatory diseases' with promising developments for brepocitinib and IMVT-1402 in the pipeline
- Management anticipates multiple catalysts in 2026, including pivotal Phase 3 readouts for brepocitinib and mosliciguat, D2T-RA study data, and potential commercial launches
- Despite 61.21% revenue shortfall and 22.58% EPS miss, investor confidence remains high, possibly due to pipeline potential and strategic positioning in markets with high unmet needs
Last Updated: 02/06/2026, 09:32 AM
Read Full TranscriptRoivant Sciences investor slides for Q3/2026
Last Update: Feb 06, 2026
See full investor slides
Compare ROIV to Peers and Sector
Metrics to compare | ROIV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipROIVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −26.0x | −9.3x | −0.5x | |
PEG Ratio | 0.04 | 0.02 | 0.00 | |
Price / Book | 4.9x | 3.7x | 2.6x | |
Price / LTM Sales | 1,580.3x | 10.3x | 3.2x | |
Upside (Analyst Target) | 19.3% | 51.3% | 47.6% | |
Fair Value Upside | Unlock | 2.5% | 6.1% | Unlock |
Analyst Ratings
12 Buy
1 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.750
(+14.83% Upside)
Earnings
Latest Release
Feb 06, 2026
EPS / Forecast
-0.38 / -0.31
Revenue / Forecast
1.99M / 5.13M
People Also Watch
FAQ
What Is the Roivant Sciences (ROIV) Stock Price Today?
The Roivant Sciences stock price today is 29.390 USD.
What Stock Exchange Does Roivant Sciences Trade On?
Roivant Sciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Roivant Sciences?
The stock symbol for Roivant Sciences is "ROIV."
What Is the Roivant Sciences Market Cap?
As of today, Roivant Sciences market cap is 20.980B USD.
What Is Roivant Sciences's Earnings Per Share (TTM)?
The Roivant Sciences EPS (TTM) is -1.173.
When Is the Next Roivant Sciences Earnings Date?
Roivant Sciences will release its next earnings report on May 28, 2026.
From a Technical Analysis Perspective, Is ROIV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Roivant Sciences Stock Split?
Roivant Sciences has split 0 times.
How Many Employees Does Roivant Sciences Have?
Roivant Sciences has 750 employees.
What is the current trading status of Roivant Sciences (ROIV)?
As of Apr 15, 2026, Roivant Sciences (ROIV) is trading at a price of 29.390 USD, with a previous close of 29.120 USD. The stock has fluctuated within a day range of 28.855 USD to 29.490 USD, while its 52-week range spans from 9.895 USD to 30.330 USD.
What Is Roivant Sciences (ROIV) Price Target According to Analysts?
The average 12-month price target for Roivant Sciences is 33.750 USD, with a high estimate of 39 USD and a low estimate of 22 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +14.83% Upside potential.
What Is the ROIV Premarket Price?
ROIV's last pre-market stock price is 29.300 USD. The pre-market share volume is 8,540.000, and the stock has decreased by 0.180, or 0.620%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.